Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:2344-2351
doi: 10.1161/CIRCULATIONAHA.106.685313
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cutlip, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cutlip, D. E.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Clinical Trials
Related Collections
Right arrow AHA Statements and Guidelines
Right arrow Catheter-based coronary interventions: stents

(Circulation. 2007;115:2344-2351.)
© 2007 American Heart Association, Inc.


Special Reports

Clinical End Points in Coronary Stent Trials

A Case for Standardized Definitions

Donald E. Cutlip, MD; Stephan Windecker, MD; Roxana Mehran, MD; Ashley Boam, MSBE; David J. Cohen, MD; Gerrit-Anne van Es, PhD, MSc; P. Gabriel Steg, MD; Marie-angèle Morel, BSc; Laura Mauri, MD, MSc; Pascal Vranckx, MD; Eugene McFadden, MD; Alexandra Lansky, MD; Martial Hamon, MD; Mitchell W. Krucoff, MD; Patrick W. Serruys, MD, on behalf of the Academic Research Consortium

From Harvard Clinical Research Institute (D.E.C., D.J.C., L.M.), Harvard Medical School, Boston, Mass; University Hospital (S.W.), Bern, Switzerland; Cardiovascular Research Foundation (R.M., A.L.), Columbia University, New York, NY; The US Food and Drug Administration (A.B.), Rockville, Md; Cardialysis (G.v.-E., M.M.), Rotterdam, the Netherlands; CHU Bichat (P.G.S.), Paris, France; Hospital Virga Jesse (P.V.), Hasselt, Belgium; University Hospital (E.M.), Cork, Ireland; CHU Caen (M.H.), Normandy, France; Duke Clinical Research Institute (M.W.K.), Duke University, Durham, NC; Erasmus Medical Center (P.W.S.), Thoraxcenter, Rotterdam, the Netherlands.

Correspondence to Donald E. Cutlip, MD, Harvard Clinical Research Institute, 930 Commonwealth Avenue, Boston, MA 02215. E-mail dcutlip{at}bidmc.harvard.edu

Background— Although most clinical trials of coronary stents have measured nominally identical safety and effectiveness end points, differences in definitions and timing of assessment have created confusion in interpretation.

Methods and Results— The Academic Research Consortium is an informal collaboration between academic research organizations in the United States and Europe. Two meetings, in Washington, DC, in January 2006 and in Dublin, Ireland, in June 2006, sponsored by the Academic Research Consortium and including representatives of the US Food and Drug Administration and all device manufacturers who were working with the Food and Drug Administration on drug-eluting stent clinical trial programs, were focused on consensus end point definitions for drug-eluting stent evaluations. The effort was pursued with the objective to establish consistency among end point definitions and provide consensus recommendations. On the basis of considerations from historical legacy to key pathophysiological mechanisms and relevance to clinical interpretability, criteria for assessment of death, myocardial infarction, repeat revascularization, and stent thrombosis were developed. The broadly based consensus end point definitions in this document may be usefully applied or recognized for regulatory and clinical trial purposes.

Conclusion— Although consensus criteria will inevitably include certain arbitrary features, consensus criteria for clinical end points provide consistency across studies that can facilitate the evaluation of safety and effectiveness of these devices.


Key Words: restenosis • stents • thrombosis • clinical trials




This article has been cited by other articles:


Home page
EuropaceHome page
P. Halbfass, S. Janko, U. Dorwarth, G. Riess, D. Antoni, and E. Hoffmann
Dilemma of antithrombotic therapy in anticoagulated atrial fibrillation patients squeezed between thrombosis and bleeding events: a single-centre experience
Europace, July 1, 2009; 11(7): 957 - 960.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
N Kukreja, P W Serruys, B De Bruyne, A Colombo, C Macaya, G Richardt, J Fajadet, C Hamm, D Goedhart, N Macours, et al.
Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior descending artery: analysis of the Arterial Revascularization Therapies study part 2 (ARTS-II)
Heart, July 1, 2009; 95(13): 1061 - 1066.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. Thiele, P. Neumann-Schniedewind, S. Jacobs, E. Boudriot, T. Walther, F.-W. Mohr, G. Schuler, and V. Falk
Randomized Comparison of Minimally Invasive Direct Coronary Artery Bypass Surgery Versus Sirolimus-Eluting Stenting in Isolated Proximal Left Anterior Descending Coronary Artery Stenosis
J. Am. Coll. Cardiol., June 23, 2009; 53(25): 2324 - 2331.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Unverdorben, C. Vallbracht, B. Cremers, H. Heuer, C. Hengstenberg, C. Maikowski, G. S. Werner, D. Antoni, F. X. Kleber, W. Bocksch, et al.
Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis
Circulation, June 16, 2009; 119(23): 2986 - 2994.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
Y. Onuma, P. Serruys, P. den Heijer, K. S. Joesoef, H. Duckers, E. Regar, N. Kukreja, S. Tanimoto, H. M. Garcia-Garcia, H. van Beusekom, et al.
MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses
Eur. Heart J., June 2, 2009; 30(12): 1477 - 1485.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
R. Chacko, M. Mulhearn, V. Novack, L. Novack, L. Mauri, S. A. Cohen, J. Moses, M. B. Leon, and D. E. Cutlip
Impact of Target Lesion and Nontarget Lesion Cardiac Events on 5-Year Clinical Outcomes After Sirolimus-Eluting or Bare-Metal Stenting
J. Am. Coll. Cardiol. Intv., June 1, 2009; 2(6): 498 - 503.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
M. B. Leon, D. J. Allocco, K. D. Dawkins, and D. S. Baim
Late Clinical Events After Drug-Eluting Stents: The Interplay Between Stent-Related and Natural History-Driven Events
J. Am. Coll. Cardiol. Intv., June 1, 2009; 2(6): 504 - 512.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
E. Di Lorenzo, G. De Luca, R. Sauro, A. Varricchio, M. Capasso, T. Lanzillo, F. Manganelli, C. Mariello, F. Siano, M. R. Pagliuca, et al.
The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial
J. Am. Coll. Cardiol. Intv., June 1, 2009; 2(6): 515 - 523.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
N. Kukreja, Y. Onuma, H. M. Garcia-Garcia, J. Daemen, R. van Domburg, P. W. Serruys, and on behalf of the Interventional cardiologists of t
The Risk of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Bare-Metal and Drug-Eluting Stents
J. Am. Coll. Cardiol. Intv., June 1, 2009; 2(6): 534 - 541.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
S. Anwaruddin, A. T. Askari, H. Saudye, L. Batizy, P. L. Houghtaling, M. Alamoudi, M. Militello, K. Muhammad, S. Kapadia, and S. G. Ellis
Characterization of Post-Operative Risk Associated With Prior Drug-Eluting Stent Use
J. Am. Coll. Cardiol. Intv., June 1, 2009; 2(6): 542 - 549.
[Abstract] [Full Text] [PDF]


Home page
Circ Cardiovasc InterventHome page
B. Chevalier, S. Silber, S.-J. Park, E. Garcia, G. Schuler, H. Suryapranata, J. Koolen, K. E. Hauptmann, W. Wijns, M.-C. Morice, et al.
Randomized Comparison of the Nobori Biolimus A9-Eluting Coronary Stent With the Taxus Liberte Paclitaxel-Eluting Coronary Stent in Patients With Stenosis in Native Coronary Arteries: The NOBORI 1 Trial--Phase 2
Circ Cardiovasc Intervent, June 1, 2009; 2(3): 188 - 195.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. Mehilli, A. Kastrati, R. A. Byrne, O. Bruskina, R. Iijima, S. Schulz, J. Pache, M. Seyfarth, S. Massberg, K.-L. Laugwitz, et al.
Paclitaxel- Versus Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease
J. Am. Coll. Cardiol., May 12, 2009; 53(19): 1760 - 1768.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
G. W. Stone, A. J. Lansky, S. J. Pocock, B. J. Gersh, G. Dangas, S. C. Wong, B. Witzenbichler, G. Guagliumi, J. Z. Peruga, B. R. Brodie, et al.
Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction
N. Engl. J. Med., May 7, 2009; 360(19): 1946 - 1959.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. Vaquerizo, T. Lefevre, O. Darremont, M. Silvestri, Y. Louvard, J. L. Leymarie, P. Garot, H. Routledge, F. de Marco, T. Unterseeh, et al.
Unprotected Left Main Stenting in the Real World: Two-Year Outcomes of the French Left Main Taxus Registry
Circulation, May 5, 2009; 119(17): 2349 - 2356.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. W. van Werkum, A. A. Heestermans, A. C. Zomer, J. C. Kelder, M.-J. Suttorp, B. J. Rensing, J. J. Koolen, B.R. G. Brueren, J.-H. E. Dambrink, R. W. Hautvast, et al.
Predictors of Coronary Stent Thrombosis: The Dutch Stent Thrombosis Registry
J. Am. Coll. Cardiol., April 21, 2009; 53(16): 1399 - 1409.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
D. Sibbing, J. Stegherr, W. Latz, W. Koch, J. Mehilli, K. Dorrler, T. Morath, A. Schomig, A. Kastrati, and N. von Beckerath
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
Eur. Heart J., April 2, 2009; 30(8): 916 - 922.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
R. A. Byrne, J. Mehilli, R. Iijima, S. Schulz, J. Pache, M. Seyfarth, A. Schomig, A. Kastrati, and for the Intracoronary Stenting and Angiographic Re
A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents
Eur. Heart J., April 2, 2009; 30(8): 923 - 931.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. M. Ruiz-Nodar, F. Marin, J. Sanchez-Paya, J. A. Hurtado, J. Valencia-Martin, S. Manzano-Fernandez, V. Roldan, V. Perez-Andreu, F. Sogorb, M. Valdes, et al.
Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation
Eur. Heart J., April 2, 2009; 30(8): 932 - 939.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
R. A. Byrne, R. Iijima, J. Mehilli, S. Pinieck, O. Bruskina, A. Schomig, and A. Kastrati
Durability of Antirestenotic Efficacy in Drug-Eluting Stents With and Without Permanent Polymer
J. Am. Coll. Cardiol. Intv., April 1, 2009; 2(4): 291 - 299.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
Y. Han, Q. Jing, B. Xu, L. Yang, H. Liu, X. Shang, T. Jiang, Z. Li, H. Zhang, H. Li, et al.
Safety and Efficacy of Biodegradable Polymer-Coated Sirolimus-Eluting Stents in "Real-World" Practice: 18-Month Clinical and 9-Month Angiographic Outcomes
J. Am. Coll. Cardiol. Intv., April 1, 2009; 2(4): 303 - 309.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. J. Eisenberg, P. R. Richard, D. Libersan, and K. B. Filion
Safety of Short-Term Discontinuation of Antiplatelet Therapy in Patients With Drug-Eluting Stents
Circulation, March 31, 2009; 119(12): 1634 - 1642.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Verheye, P. Agostoni, C. L. Dubois, J. Dens, J. Ormiston, S. Worthley, B. Trauthen, T. Hasegawa, B.-K. Koo, P. J. Fitzgerald, et al.
9-Month Clinical, Angiographic, and Intravascular Ultrasound Results of a Prospective Evaluation of the Axxess Self-Expanding Biolimus A9-Eluting Stent in Coronary Bifurcation Lesions: The DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) Study
J. Am. Coll. Cardiol., March 24, 2009; 53(12): 1031 - 1039.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. S. Brilakis, C. Lichtenwalter, J. A. de Lemos, M. Roesle, O. Obel, D. Haagen, B. Saeed, C. Gadiparthi, J. K. Bissett, R. Sachdeva, et al.
A Randomized Controlled Trial of a Paclitaxel-Eluting Stent Versus a Similar Bare-Metal Stent in Saphenous Vein Graft Lesions: The SOS (Stenting Of Saphenous Vein Grafts) Trial
J. Am. Coll. Cardiol., March 17, 2009; 53(11): 919 - 928.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. Sibbing, S. Braun, T. Morath, J. Mehilli, W. Vogt, A. Schomig, A. Kastrati, and N. von Beckerath
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
J. Am. Coll. Cardiol., March 10, 2009; 53(10): 849 - 856.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
A. R. Galassi, S. D. Tomasello, D. Capodanno, G. Barrano, G. P. Ussia, and C. Tamburino
Mini-Crush Versus T-Provisional Techniques in Bifurcation Lesions: Clinical and Angiographic Long-Term Outcome After Implantation of Drug-Eluting Stents
J. Am. Coll. Cardiol. Intv., March 1, 2009; 2(3): 185 - 194.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
C. Tamburino, A. La Manna, M. E. Di Salvo, G. Sacchetta, D. Capodanno, R. Mehran, G. Dangas, T. Corcos, and F. Prati
First-in-Man 1-Year Clinical Outcomes of the Catania Coronary Stent System With Nanothin Polyzene-F in De Novo Native Coronary Artery Lesions: The ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) Trial
J. Am. Coll. Cardiol. Intv., March 1, 2009; 2(3): 197 - 204.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
S. Verheye, P. Agostoni, K. D. Dawkins, J. Dens, W. Rutsch, D. Carrie, J. Schofer, C. Lotan, C. L. Dubois, S. A. Cohen, et al.
The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) Trial
J. Am. Coll. Cardiol. Intv., March 1, 2009; 2(3): 205 - 214.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
E. Mahmud, J. A. Ormiston, M. A. Turco, J. J. Popma, N. J. Weissman, C. D. O'Shaughnessy, T. Mann, J. J. Hall, T. F. McGarry, L. A. Cannon, et al.
TAXUS Liberte Attenuates the Risk of Restenosis in Patients With Medically Treated Diabetes Mellitus: Results From the TAXUS ATLAS Program
J. Am. Coll. Cardiol. Intv., March 1, 2009; 2(3): 240 - 252.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. W. van Werkum, A. A.C.M. Heestermans, F. I. de Korte, J. C. Kelder, M.-J. Suttorp, B. J.W.M. Rensing, B. Zwart, B. R. G. Brueren, J. J. Koolen, J.-H. E. Dambrink, et al.
Long-Term Clinical Outcome After a First Angiographically Confirmed Coronary Stent Thrombosis: An Analysis of 431 Cases
Circulation, February 17, 2009; 119(6): 828 - 834.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Windecker and P. Juni
The Drug-Eluting Stent Saga
Circulation, February 10, 2009; 119(5): 653 - 656.
[Full Text] [PDF]


Home page
CirculationHome page
G. W. Stone, M. Midei, W. Newman, M. Sanz, J. B. Hermiller, J. Williams, N. Farhat, R. Caputo, N. Xenopoulos, R. Applegate, et al.
Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: Two-Year Clinical Follow-Up From the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) III Trial
Circulation, February 10, 2009; 119(5): 680 - 686.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
N. Piazza, Y. Onuma, P. de Jaegere, and P. W. Serruys
Guidelines for reporting mortality and morbidity after cardiac valve interventions--need for a reappraisal?
Ann. Thorac. Surg., February 1, 2009; 87(2): 357 - 358.
[Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
D. E. Kandzari, S. V. Rao, J. W. Moses, V. Dzavik, B. H. Strauss, M. J. Kutryk, C. A. Simonton, J. Garg, Y. Lokhnygina, G.B. J. Mancini, et al.
Clinical and Angiographic Outcomes With Sirolimus-Eluting Stents in Total Coronary Occlusions: The ACROSS/TOSCA-4 (Approaches to Chronic Occlusions With Sirolimus-Eluting Stents/Total Occlusion Study of Coronary Arteries-4) Trial
J. Am. Coll. Cardiol. Intv., February 1, 2009; 2(2): 97 - 106.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A. K.M. Hassan, S. C. Bergheanu, T. Stijnen, B. L. van der Hoeven, J. D. Snoep, J. W.M. Plevier, M. J. Schalij, and J. W. Jukema
Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis
Eur. Heart J., January 21, 2009; (2009) ehn553v1.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Colombo, E. Bramucci, S. Sacca, R. Violini, C. Lettieri, R. Zanini, I. Sheiban, L. Paloscia, E. Grube, J. Schofer, et al.
Randomized Study of the Crush Technique Versus Provisional Side-Branch Stenting in True Coronary Bifurcations: The CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study
Circulation, January 6, 2009; 119(1): 71 - 78.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
Authors/writing members:, J. Daemen, M. L. Simoons, W. Wijns, A. Bagust, G. Bos, J. M. Bowen, E. Braunwald, E. Camenzind, B. Chevalier, et al.
Meeting Report: ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007
Eur. Heart J., January 2, 2009; 30(2): 152 - 161.
[Full Text] [PDF]


Home page
Eur Heart JHome page
M. Pfisterer, H. P. Brunner-La Rocca, P. Rickenbacher, P. Hunziker, C. Mueller, F. Nietlispach, G. Leibundgut, F. Bader, C. Kaiser, and for the BASKET Investigators
Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET
Eur. Heart J., January 1, 2009; 30(1): 16 - 24.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S.-J. Park and Y.-H. Kim
Current Status of Percutaneous Coronary Intervention With Drug-Eluting Stents in Asia
Circulation, December 16, 2008; 118(25): 2730 - 2737.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. Daemen, K. H. Kuck, C. Macaya, V. LeGrand, M. Vrolix, D. Carrie, I. Sheiban, M. J. Suttorp, P. Vranckx, T. Rademaker, et al.
Multivessel Coronary Revascularization in Patients With and Without Diabetes Mellitus: 3-Year Follow-Up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) Trial
J. Am. Coll. Cardiol., December 9, 2008; 52(24): 1957 - 1967.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
F. Burzotta, A. Parma, C. Pristipino, A. Manzoli, F. Belloni, G. Sardella, S. Rigattieri, A. Danesi, P. Mazzarotto, F. Summaria, et al.
Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study
Eur. Heart J., December 2, 2008; 29(24): 3011 - 3021.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Rodes-Cabau, J. DeBlois, O. F. Bertrand, S. Mohammadi, J. Courtis, E. Larose, F. Dagenais, J.-P. Dery, P. Mathieu, M. Rousseau, et al.
Nonrandomized Comparison of Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention for the Treatment of Unprotected Left Main Coronary Artery Disease in Octogenarians
Circulation, December 2, 2008; 118(23): 2374 - 2381.
[Abstract] [Full Text] [PDF]


Home page
Circ Cardiovasc InterventHome page
L. O. Jensen, M. Maeng, P. Thayssen, A. Kaltoft, H. H. Tilsted, M. Bottcher, J. F. Lassen, K. N. Hansen, L. R. Krusell, K. Rasmussen, et al.
Clinical Outcome After Primary Percutaneous Coronary Intervention With Drug-Eluting and Bare Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction
Circ Cardiovasc Intervent, December 1, 2008; 1(3): 176 - 184.
[Abstract] [Full Text] [PDF]


Home page
Circ Cardiovasc InterventHome page
A. Colombo and R. T. Gerber
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Not Be Continued for More Than 1 Year and Preferably Indefinitely
Circ Cardiovasc Intervent, December 1, 2008; 1(3): 226 - 232.
[Full Text] [PDF]


Home page
Eur Heart JHome page
T. Adriaenssens, R. A. Byrne, A. Dibra, R. Iijima, J. Mehilli, O. Bruskina, A. Schomig, and A. Kastrati
Culotte stenting technique in coronary bifurcation disease: angiographic follow-up using dedicated quantitative coronary angiographic analysis and 12-month clinical outcomes
Eur. Heart J., December 1, 2008; 29(23): 2868 - 2876.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
M. A. Turco, J. A. Ormiston, J. J. Popma, J. J. Hall, T. Mann, L. A. Cannon, M. W.I. Webster, G. J. Mishkel, C. D. O'Shaughnessy, T. F. McGarry, et al.
Reduced Risk of Restenosis in Small Vessels and Reduced Risk of Myocardial Infarction in Long Lesions With the New Thin-Strut TAXUS Liberte Stent: 1-Year Results From the TAXUS ATLAS Program
J. Am. Coll. Cardiol. Intv., December 1, 2008; 1(6): 699 - 709.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
F. Alfonso, M.-J. Perez-Vizcayno, R. Hernandez, A. Bethencourt, V. Marti, J. R. Lopez-Minguez, J. Angel, A. Iniguez, C. Moris, A. Cequier, et al.
Long-Term Clinical Benefit of Sirolimus-Eluting Stents in Patients With In-Stent Restenosis: Results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) Study
J. Am. Coll. Cardiol., November 11, 2008; 52(20): 1621 - 1627.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. Meliga, A. O. Maree, H. M. Garcia-Garcia, and P. W. Serruys
Reply
J. Am. Coll. Cardiol., November 11, 2008; 52(20): 1681 - 1681.
[Full Text] [PDF]


Home page
Eur Heart JHome page
L. O. Jensen, M. Maeng, P. Thayssen, E. H. Christiansen, K. N. Hansen, A. Galloe, H. Kelbaek, J. F. Lassen, and L. Thuesen
Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: The Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial
Eur. Heart J., November 2, 2008; 29(22): 2733 - 2741.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
R. A. Byrne and A. Kastrati
Duration of antiplatelet therapy following intracoronary stenting: are changes needed?
Eur. Heart J. Suppl., November 1, 2008; 10(suppl_I): I25 - I29.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Barlis, K. Dimopoulos, and C. Di Mario
Letter by Barlis et al Regarding Article, "Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions: Results From a Real-World Multicenter Registry
Circulation, October 28, 2008; 118(18): e679 - e679.
[Full Text] [PDF]


Home page
CirculationHome page
P. Ortolani, F. Saia, R. M.T. Cooke, A. Marzocchi, M. Balducelli, A. Maresta, P. Marzaroli, P. Guastaroba, R. Grilli, G. Piovaccari, et al.
Response to Letters Regarding Article, "Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions: Results From a Real-World Multicenter Registry"
Circulation, October 28, 2008; 118(18): e681 - e681.
[Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
D.-W. Park, S.-C. Yun, S.-W. Lee, Y.-H. Kim, C. W. Lee, M.-K. Hong, S.-S. Cheong, J.-J. Kim, S.-W. Park, and S.-J. Park
Stent Thrombosis, Clinical Events, and Influence of Prolonged Clopidogrel Use After Placement of Drug-Eluting Stent: Data From an Observational Cohort Study of Drug-Eluting Versus Bare-Metal Stents
J. Am. Coll. Cardiol. Intv., October 1, 2008; 1(5): 494 - 503.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
B. Chevalier, C. Di Mario, F.-J. Neumann, F. Ribichini, P. Urban, J. J. Popma, P. J. Fitzgerald, D. E. Cutlip, D. O. Williams, J. Ormiston, et al.
A Randomized, Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zotarolimus- Versus Paclitaxel-Eluting Stents in De Novo Occlusive Lesions in Coronary Arteries: The ZoMaxx I Trial
J. Am. Coll. Cardiol. Intv., October 1, 2008; 1(5): 524 - 532.
[Abstract] [Full Text] [PDF]


Home page
Circ Cardiovasc InterventHome page
N. Kukreja, Y. Onuma, H. Garcia-Garcia, J. Daemen, R. van Domburg, and P. W. Serruys
Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Long-Term Outcome After Bare Metal and Drug-Eluting Stent Implantation
Circ Cardiovasc Intervent, October 1, 2008; 1(2): 103 - 110.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Wenaweser, J. Daemen, M. Zwahlen, R. van Domburg, P. Juni, S. Vaina, G. Hellige, K. Tsuchida, C. Morger, E. Boersma, et al.
Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice: 4-Year Results From a Large 2-Institutional Cohort Study
J. Am. Coll. Cardiol., September 30, 2008; 52(14): 1134 - 1140.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. E. Pfisterer
Late Stent Thrombosis After Drug-Eluting Stent Implantation for Acute Myocardial Infarction: A New Red Flag Is Raised
Circulation, September 9, 2008; 118(11): 1117 - 1119.
[Full Text] [PDF]


Home page
CirculationHome page
H. Kelbaek, L. Thuesen, S. Helqvist, P. Clemmensen, L. Klovgaard, A. Kaltoft, B. Andersen, H. Thuesen, T. Engstrom, H. E. Botker, et al.
Drug-Eluting Versus Bare Metal Stents in Patients With ST-Segment-Elevation Myocardial Infarction: Eight-Month Follow-Up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) Trial
Circulation, September 9, 2008; 118(11): 1155 - 1162.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
C. Stettler, S. Allemann, S. Wandel, A. Kastrati, M. C. Morice, A. Schomig, M. E Pfisterer, G. W Stone, M. B Leon, J. S. d. Lezo, et al.
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis
BMJ, August 29, 2008; 337(aug29_3): a1331 - a1331.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. Mehilli, R. A. Byrne, A. Wieczorek, R. Iijima, S. Schulz, O. Bruskina, J. Pache, R. Wessely, A. Schomig, A. Kastrati, et al.
Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis
Eur. Heart J., August 2, 2008; 29(16): 1975 - 1982.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
H. C. Routledge, M.-C. Morice, T. Lefevre, P. Garot, F. De Marco, B. Vaquerizo, and Y. Louvard
2-Year Outcome of Patients Treated for Bifurcation Coronary Disease With Provisional Side Branch T-Stenting Using Drug-Eluting Stents
J. Am. Coll. Cardiol. Intv., August 1, 2008; 1(4): 358 - 365.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S. G. Ellis, C. D. O'Shaughnessy, S. L. Martin, K. Kent, T. McGarry, M. A. Turco, D. J. Kereiakes, J. J. Popma, M. Friedman, J. Koglin, et al.
Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial
Eur. Heart J., July 1, 2008; 29(13): 1625 - 1634.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
D. J. Malenka, A. V. Kaplan, F. L. Lucas, S. M. Sharp, and J. S. Skinner
Outcomes Following Coronary Stenting in the Era of Bare-Metal vs the Era of Drug-Eluting Stents
JAMA, June 25, 2008; 299(24): 2868 - 2876.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. Mahmud, G. Bromberg-Marin, V. Palakodeti, L. Ang, D. Creanga, and A. N. DeMaria
Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis.
J. Am. Coll. Cardiol., June 24, 2008; 51(25): 2385 - 2395.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. Chechi, S. Vecchio, G. Vittori, G. Giuliani, A. Lilli, G. Spaziani, L. Consoli, G. Baldereschi, G. G.L. Biondi-Zoccai, I. Sheiban, et al.
ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients.
J. Am. Coll. Cardiol., June 24, 2008; 51(25): 2396 - 2402.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. Meliga, H. M. Garcia-Garcia, M. Valgimigli, A. Chieffo, G. Biondi-Zoccai, A. O. Maree, S. Cook, L. Reardon, C. Moretti, S. De Servi, et al.
Longest available clinical outcomes after drug-eluting stent implantation for unprotected left main coronary artery disease: the DELFT (Drug Eluting stent for LeFT main) Registry.
J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2212 - 2219.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
D. Austin, J. P. Pell, K. G. Oldroyd, P. Agostoni, P. Vermeersch, O. C. Marroquin, S. R. Mulukutla, and K. E. Kip
Bare-Metal versus Drug-Eluting Coronary Stents
N. Engl. J. Med., June 5, 2008; 358(23): 2516 - 2518.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. Kelbaek, L. Klovgaard, S. Helqvist, J. F. Lassen, L. R. Krusell, T. Engstrom, H. E. Botker, E. Jorgensen, K. Saunamaki, S. Aljabbari, et al.
Long-Term Outcome in Patients Treated With Sirolimus-Eluting Stents in Complex Coronary Artery Lesions: 3-Year Results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) Trial
J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2011 - 2016.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
G. W. Stone, B. Witzenbichler, G. Guagliumi, J. Z. Peruga, B. R. Brodie, D. Dudek, R. Kornowski, F. Hartmann, B. J. Gersh, S. J. Pocock, et al.
Bivalirudin during Primary PCI in Acute Myocardial Infarction
N. Engl. J. Med., May 22, 2008; 358(21): 2218 - 2230.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Garg, D. J. Cohen, T. Gaziano, and L. Mauri
Balancing the Risks of Restenosis and Stent Thrombosis in Bare-Metal Versus Drug-Eluting Stents: Results of a Decision Analytic Model
J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1844 - 1853.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
G. W. Stone, M. Midei, W. Newman, M. Sanz, J. B. Hermiller, J. Williams, N. Farhat, K. W. Mahaffey, D. E. Cutlip, P. J. Fitzgerald, et al.
Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease: A Randomized Trial
JAMA, April 23, 2008; 299(16): 1903 - 1913.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
M. R. Patel and D. R. Holmes Jr
Next-Generation Drug-Eluting Stents: A Spirited Step Forward or More of the Same
JAMA, April 23, 2008; 299(16): 1952 - 1953.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. W. Krucoff, D. J. Kereiakes, J. L. Petersen, R. Mehran, V. Hasselblad, A. J. Lansky, P. J. Fitzgerald, J. Garg, M. A. Turco, C. A. Simonton III, et al.
A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
J. Am. Coll. Cardiol., April 22, 2008; 51(16): 1543 - 1552.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
M. Valgimigli, G. Campo, G. Percoco, L. Bolognese, C. Vassanelli, S. Colangelo, N. de Cesare, A. E. Rodriguez, M. Ferrario, R. Moreno, et al.
Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction: The MULTISTRATEGY Randomized Trial
JAMA, April 16, 2008; 299(15): 1788 - 1799.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. J. Zellweger, C. Kaiser, H. P. Brunner-La Rocca, P. T. Buser, S. Osswald, P. Weiss, J. Mueller-Brand, M. E. Pfisterer, and for the BASKET Investigators
Value and Limitations of Target-Vessel Ischemia in Predicting Late Clinical Events After Drug-Eluting Stent Implantation
J. Nucl. Med., April 1, 2008; 49(4): 550 - 556.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Pfisterer, H. P. Brunner-La Rocca, and C. Kaiser
The balance of risks and benefits of drug-eluting versus bare-metal stents.
J. Am. Coll. Cardiol., March 4, 2008; 51(9): 972 - 972.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. L. Dauerman
Percutaneous Coronary Intervention Pharmacology From a Triangle to a Square.
J. Am. Coll. Cardiol., February 19, 2008; 51(7): 698 - 700.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. E. Kip, K. Hollabaugh, O. C. Marroquin, and D. O. Williams
The Problem With Composite End Points in Cardiovascular Studies The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention.
J. Am. Coll. Cardiol., February 19, 2008; 51(7): 701 - 707.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. J. Kirtane, S. G. Ellis, K. D. Dawkins, A. Colombo, E. Grube, J. J. Popma, M. Fahy, M. B. Leon, J. W. Moses, R. Mehran, et al.
Paclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus Pooled Analysis From 5 Randomized Trials.
J. Am. Coll. Cardiol., February 19, 2008; 51(7): 708 - 715.
[Abstract] [Full Text] [PDF]


Home page
Ther Adv Cardiovasc DisHome page
F. Saia, A. Marzocchi, and A. Branzi
Review: The safety of drug-eluting stents
Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 43 - 52.
[Abstract] [PDF]